A common painkiller can be a promising treatment for cancer. A new study has stated that diclofenac might be more than a painkiller.</p></p>According to researchers workin

A common painkiller can be a promising treatment for cancer. A new study has stated that diclofenac might be more than a painkiller.

According to researchers working on the Repurposing Drugs in Oncology (ReDO) project, the painkiller exhibits mechanisms that not only address pain but also function in developing new blood vessels.

This paper focuses on the evidence of an anticancer effect of DCF treatment, including data that is specific to DCF and other data that is in line with DCF s effects as an NSAID. In particular the emphasis is on DCF treatment post-diagnosis rather than on evidence of efficacy in a cancer chemo-prevention context.

The non-steroidal anti-inflammatory drug (NSAID) diclofenac was revealed in a news release to have properties that can potentially cure cancer.

There are currently four clinical trials investigating diclofenac’s effects on cancer, including three that use the painkiller as part of TL-118, an experimental four-drug combination.

The project, which is a joint venture of GlobalCures (U.S.) and the Anticancer Fund (Belgium), is responsible for analyzing if any existing medication has anti-cancer properties. Study author Pan Pantziarka said, It s still somewhat surprising that there is still so much we don t understand about how many of the standard drugs we use every day, like diclofenac, work.

The study was published in ecancermedicalscience. Researchers analyzed various studies dating back to 1983. These studies state that diclofenac could have anti-tumor effects.

Demonstrative study of medical records for patients have shown that diclofenac has had an important effect on the risk of metastasis and lesser mortality. Patients with a range of cancers were treated with diclofenac before surgery.

It was stated by the research team that this finding can lead to better cancer treatments in the times to come. Pantziarka stated that diclofenac may have actions that synergise with the most recent generation of checkpoint inhibitors, the mixture of the latest drugs in the anticancer armoury with some of the oldest is especially exciting.

Pantziarka said the studies may show NSAIDs have a consequence of averting metastasis in patients with cancer.